Human Immunodeficiency Virus (Hiv) Attacks The Body’s Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.
The Global Hiv Drugs Market Was Valued At $20,448 Million In 2015, And Is Estimated To Reach $26,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.
The Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.
Key Benefits for Stakeholders
The Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.
It Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.
Extensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.
Key Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.
HIV Drug Market Key Segments
By Medication Class
Multi-Class Combination Drugs
Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
Viramune (Immediate Release)
Protease Inhibitors (Pis)
Hiv Integrase Stand Transfer Inhibitors
List Of Key Players Profiled in the Report
Boehringer Ingelheim International Gmbh
Merck & Co.
Gilead Sciences Inc.
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
List Of Other Players in the Value Chain
(These Players Are Not Profiled In The Report. The Same Will Be Included On Request)
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS
CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS
4.2. MULTI-CLASS COMBINATION DRUGS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Atripla: market size and forecast
4.2.5. Complera: market size and forecast
4.2.6. Prezista: market size and forecast
4.2.7. Stribild: market size and forecast
4.2.8. Triumeq: market size and forecast
4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Combivir: market size and forecast
4.3.5. Emtriva: market size and forecast
4.3.6. Epivir: market size and forecast
4.3.7. Epzicom: market size and forecast
4.3.8. Trizivir: market size and forecast
4.3.9. Truvada: market size and forecast
4.3.10. Viread: market size and forecast
4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Edurant: market size and forecast
4.4.5. Rescriptor: market size and forecast
4.4.6. Sustiva: market size and forecast
4.4.7. Viramune: market size and forecast
4.5. PROTEASE INHIBITORS (PIS)
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Aptivus: market size and forecast
4.5.5. Crixivan: market size and forecast
4.5.6. Kaletra: market size and forecast
4.5.7. Lexiva: market size and forecast
4.5.8. Norvir: market size and forecast
4.5.9. Reyataz: market size and forecast
4.5.10. Viracept: market size and forecast
4.6. FUSION INHIBITORS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Fuzeon: market size and forecast
4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Selzentry: market size and forecast
4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Isentress: market size and forecast
4.8.5. Tivicay: market size and forecast
CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves & developments
6.2. MERCK & CO., INC.
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves & developments
6.3. BRISTOL-MYERS SQUIBB
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves & developments
6.4. GILEAD SCIENCES, INC.
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves & developments
6.5. VIIV HEALTHCARE
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves & developments
6.6. JOHNSON & JOHNSON
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key Strategic Moves & Developments
6.7. F. HOFFMANN-LA ROCHE LTD
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key Strategic Moves & Developments
6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key Strategic Moves & Developments
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves & developments
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key Strategic Moves & Developments
LIST OF OTHER PLAYERS IN THE VALUE CHAIN
(These players are not profiled in the report. The same will be included on request)
HIV Drug Market report, forecasts that the global market is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the period 2016 - 2022. The multi-class combition drug segment held over one-third share of the total market in 2015.
Multi-class combition drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combition drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence. Increase in the number of HIV infected patients across the globe increases the need for effective treatment for HIV related diseases. Use of Multi-class combition products is an efficient way of treating HIV. Atripla and Prezista are among the blockbuster combition drugs used in the HIV treatment.
North America was the highest revenue contributor in 2015; this is attributed to the awareness about healthcare in the region, higher HIV diagnosis & treatment rate, ample healthcare expenditure, well-established healthcare system, and proactive government initiatives to control the spread of HIV in the North American countries. Gilead, GlaxoSmithKline, Novartis, and Merck & Co. are some of the key players in the North American HIV drugs market. However, Asia-Pacific region is projected to grow with the highest CAGR of 6.3% during the alysis period, due to the presence large HIV patient pool and ample growth opportunities in terms of unmet medical needs for magement of HIV in the region. Moreover, increase in focus & investment from leading players in the region support the growth of the HIV drugs market in the Asia-Pacific region.
Key findings of HIV Drug Market
In 2015, multi-class combition drugs segment was the leading medication class segment.
The branded drug Triumeq of multi-class combition drug segment is estimated to grow at the CAGR of 20.7%.
North America market is projected to grow at a CAGR of 3.4% during alysis period.
The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) segment is estimated to grow at the CAGR of 0.4%.
The major companies profiled in the report include Boehringer Ingelheim Intertiol GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.